Santhera Pharmaceuticals, 7.5% 17aug2024, CHF (Conv.) (FIGI BBG00ZTK5QV9, CH0563348744, WKN A3KPUR)
国内債券, 転換社債, Senior Unsecured
国内債券, 転換社債, Senior Unsecured
|
Santhera Pharmaceuticals is a Swiss drug discovery and development company. It is focused on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options. The company was founded in 2004 through the ...
Santhera Pharmaceuticals is a Swiss drug discovery and development company. It is focused on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options. The company was founded in 2004 through the merger of two start-up biotech companies, MyoContract and Graffinity Pharmaceuticals. Santhera’s headquarters are located in Liestal, Switzerland, with subsidiaries in Germany, UK, Italy, Netherlands, Liechtenstein, US and Canada.
|
|
|
|
|
|
|
|
|
最も包括的なデータベースを探索
1 000 000
債券
80 234
株
167 970
ETF&投資信託
70 000
インデックス
最も効率的な方法でポートフォリオを追跡